Brepocitinib for skin sarcoidosis
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests an oral drug called brepocitinib to see if it can help people with skin sarcoidosis and reduce skin symptoms. It aims to find a better treatment option for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of skin sarcoidosis with a skin biopsy.
- Your skin condition must be active, with a certain level of severity.
- You must weigh between 40 kg (about 88 lbs) and less than 130 kg (about 287 lbs), and your body mass index (BMI) must be 45 or lower.
- You must not have a history of cancer (except for certain fully removed skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether sirolimus (an immune-influencing medicine) can improve moderate-to-severe sarcoidosis affecting the face. It may help if you’ve tried standard sarcoidosis treatments before but they didn’t work well enough or stopped working.
This trial tests a medication called baricitinib (a JAK inhibitor) for people with active cardiac sarcoidosis. It may help reduce inflammation in the heart and improve heart function.
This trial tests if a steroid combination medicine called Compound Betamethasone works well for people recently diagnosed with pulmonary sarcoidosis who haven't yet had treatment. The goal is to see if it can control the disease with fewer side effects than usual steroids.
This trial studies a treatment approach for people with active cardiac sarcoidosis, confirmed by specific heart rhythm/heart function problems and a PET scan. It may help by targeting the active inflammation driving heart conduction problems, rhythm events, or weak heart pumping.
This trial tests a new medication called brepocitinib to treat lichen planopilaris (LPP), a condition that causes scarring and hair loss on the scalp. The study aims to see if this drug can reduce symptoms and help hair regrow.
This trial tests if rilonacept can help people with cardiac sarcoidosis, a condition where inflammation affects the heart. You may join if you have active inflammation on a PET scan despite standard treatments.
Hear when a new Cutaneous Sarcoidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.